{"id":75763,"date":"2026-08-21T12:12:54","date_gmt":"2026-08-21T04:12:54","guid":{"rendered":"https:\/\/flcube.com\/?p=75763"},"modified":"2026-08-21T12:12:55","modified_gmt":"2026-08-21T04:12:55","slug":"ultomiris-wins-nmpa-approval-for-pnh-in-china-bringing-long-acting-ravulizumab-c5-inhibitor-to-adult-and-pediatric-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75763","title":{"rendered":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ultomiris<\/strong> (ravulizumab injection), a long\u2011acting <strong>C5 complement inhibitor<\/strong> under <strong>AstraZeneca&#8217;s<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) Rare Disease business, was approved by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of adult and pediatric patients aged 1 month and older with <strong>paroxysmal nocturnal hemoglobinuria (PNH)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ultomiris (ravulizumab injection)<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Long\u2011acting C5 complement inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>PNH in adult and pediatric patients aged \u2265 1 month<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>20 Aug 2026<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>AstraZeneca Rare Disease (NYSE: AZN)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-four-phase-iii-studies\" class=\"wp-block-heading\">Clinical Evidence \u2013 Four Phase III Studies<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The approval was based on comprehensive results from three global Phase III studies and one Chinese Phase III trial, demonstrating the efficacy and safety of <strong>ravulizumab<\/strong> in both adult and pediatric <strong>PNH<\/strong> patients:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>ALXN1210\u2011PNH\u2011301<\/strong><\/td><td>Global Phase III<\/td><\/tr><tr><td><strong>ALXN1210\u2011PNH\u2011302<\/strong><\/td><td>Global Phase III<\/td><\/tr><tr><td><strong>ALXN1210\u2011PNH\u2011304<\/strong><\/td><td>Global Phase III<\/td><\/tr><tr><td><strong>ALXN1210\u2011PNH\u2011323<\/strong><\/td><td>China Phase III<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Long\u2011acting <strong>C5 complement inhibitor<\/strong> that blocks terminal complement\u2011mediated red blood cell destruction, the core driver of <strong>PNH<\/strong><\/li>\n\n\n\n<li><strong>Onset:<\/strong> Provides rapid complete C5 inhibition by the end of the first infusion<\/li>\n\n\n\n<li><strong>Durability:<\/strong> Sustained complete C5 inhibition supports extended dosing intervals versus shorter\u2011acting complement therapies<\/li>\n\n\n\n<li><strong>Approved Indications Globally:<\/strong> PNH, generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD) across multiple countries and regions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Rare\u2011Disease Access:<\/strong> The approval expands treatment options for Chinese <strong>PNH<\/strong> patients \u2014 including pediatric patients from 1 month of age \u2014 in a rare disease with historically limited therapeutic choices<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> <strong>Ultomiris&#8217;<\/strong> long\u2011acting profile reduces infusion frequency, a meaningful quality\u2011of\u2011life and adherence benefit over short\u2011acting C5 inhibitors<\/li>\n\n\n\n<li><strong>Portfolio Breadth:<\/strong> With approvals across four rare\u2011disease indications worldwide, <strong>ravulizumab<\/strong> anchors <strong>AstraZeneca&#8217;s<\/strong> Rare Disease franchise and strengthens its commercial position in China&#8217;s complement\u2011inhibitor market<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> The China entry of a long\u2011acting C5 inhibitor intensifies competition in the complement space, where factor B and other upstream mechanisms are also advancing through regulatory review<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Ultomiris&#8217; regulatory status, clinical profile, and commercial prospects in China. Actual results may differ due to risks including pricing and reimbursement negotiations, market adoption, and competitive dynamics in the complement inhibitor market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca&#8217;s (NYSE: AZN) Rare Disease business,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75764,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[130,4621,68,15,24],"class_list":["post-75763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-nyse-azn","tag-pediatric-drugs","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca&#039;s (NYSE: AZN) Rare Disease business, was approved by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult and pediatric patients aged 1 month and older with paroxysmal nocturnal hemoglobinuria (PNH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75763\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients\" \/>\n<meta property=\"og:description\" content=\"Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca&#039;s (NYSE: AZN) Rare Disease business, was approved by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult and pediatric patients aged 1 month and older with paroxysmal nocturnal hemoglobinuria (PNH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75763\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T04:12:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T04:12:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients\",\"datePublished\":\"2026-08-21T04:12:54+00:00\",\"dateModified\":\"2026-08-21T04:12:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2103.webp\",\"keywords\":[\"AstraZeneca\",\"NYSE:\u202fAZN\",\"Pediatric drugs\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75763#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75763\",\"name\":\"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2103.webp\",\"datePublished\":\"2026-08-21T04:12:54+00:00\",\"dateModified\":\"2026-08-21T04:12:55+00:00\",\"description\":\"Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca's (NYSE: AZN) Rare Disease business, was approved by China's National Medical Products Administration (NMPA) for the treatment of adult and pediatric patients aged 1 month and older with paroxysmal nocturnal hemoglobinuria (PNH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75763\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2103.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75763#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca's (NYSE: AZN) Rare Disease business, was approved by China's National Medical Products Administration (NMPA) for the treatment of adult and pediatric patients aged 1 month and older with paroxysmal nocturnal hemoglobinuria (PNH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75763","og_locale":"en_US","og_type":"article","og_title":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients","og_description":"Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca's (NYSE: AZN) Rare Disease business, was approved by China's National Medical Products Administration (NMPA) for the treatment of adult and pediatric patients aged 1 month and older with paroxysmal nocturnal hemoglobinuria (PNH).","og_url":"https:\/\/flcube.com\/?p=75763","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-21T04:12:54+00:00","article_modified_time":"2026-08-21T04:12:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75763#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75763"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients","datePublished":"2026-08-21T04:12:54+00:00","dateModified":"2026-08-21T04:12:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75763"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=75763#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp","keywords":["AstraZeneca","NYSE:\u202fAZN","Pediatric drugs","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75763#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75763","url":"https:\/\/flcube.com\/?p=75763","name":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=75763#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=75763#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp","datePublished":"2026-08-21T04:12:54+00:00","dateModified":"2026-08-21T04:12:55+00:00","description":"Ultomiris (ravulizumab injection), a long\u2011acting C5 complement inhibitor under AstraZeneca's (NYSE: AZN) Rare Disease business, was approved by China's National Medical Products Administration (NMPA) for the treatment of adult and pediatric patients aged 1 month and older with paroxysmal nocturnal hemoglobinuria (PNH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75763#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75763"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=75763#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp","width":1080,"height":608,"caption":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75763#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ultomiris Wins NMPA Approval for PNH in China, Bringing Long\u2011Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2103.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75763"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75763\/revisions"}],"predecessor-version":[{"id":75765,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75763\/revisions\/75765"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/75764"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}